Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the US market for "failed degradation specifications", according to the US Food and Drug Administration (USFDA).
USFDA noted that the New Jersey-based Biocon Pharma Inc is recalling the affected lot due to ‘Failed Impurities/Degradation Specifications: High Out Of Specification degradation results’.